India: IPAB Quibble Indian Patent Office On Rejecting Schering’s Crystalline Form Patent Of Vorapaxar

The importance of following due process when reviewing patent applications was reinforced in the recent Intellectual Property Appellate Board' (IPAB) decision which has directed the patent office to consider the patent application of US-based Schering Corporation for a crystalline form of a compound for treatment of heart related disease afresh. Schering's patent (2491/CHENP/2006) claims a crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist, vorapaxar. Vorapaxar is used for the treatment of acute coronary syndrome chest pain caused by coronary artery disease. The parent invention of the crystalline form of vorapaxar itself is yet to be fully developed as a drug.

In 2009, the Assistant Controller of Patents & Designs rejected the application based on lack of therapeutic efficacy of the crystalline form as required by Section 3(d) of the Indian Patents Act, 1970 and lack of inventive step under Section 2(i)(j)(a) of the Patents (Amendment act) 2005.However, the counsel appeared for Schering submitted that there is no data available to be provided for the therapeutic efficacy. The Counsel for the applicant added that the invention is still in the development stage and argued that the claims and contents by the appellants produced were not properly considered by the Controller thereby the order failed to substantiate the reason for refusal of the patent. The counsel for the Controller replied that the reasons for refusals were included in the order and mentioned the Section 3(d) of the Patents Act, in connection to the case.

IPAB's stance on Schering Corporation vs Asst. Controller of Patents & Designs

In an order issued by IPAB, the board stated that the Controller had passed a cryptic and wrong speaking order. IPAB also stated that the applicant was not given an opportunity to substantiate and discuss his claims and thereby rendering finding on each and every aspect. Pertinent to the present case, IPAB quoted Section 15 of the Patents Act, which reads hereunder:

"Where the Controller is satisfied that the application or any specification or any other document filed in pursuance thereof does not comply with the requirements of this Act or of any rules made there under, the Controller may refuse the application or may require the application, specification or the other documents, as the case may be, to be amended to his satisfaction before he proceeds with the application and refuse the application on failure to do so."1

The aforesaid provision clearly indicate that the Assistant Controller resorted to passing judgment superficially rather than exercising his discretion in giving an opportunity to the applicant in making amendments in the application.

"The reading of the above said provisions makes it abundantly clear that the learned Controller ought not to have mechanically refused the application and on the other hand he could have exercised discretion to give opportunity to the applicant/appellant by making amendments in the application. As submitted by the learned counsel for the appellant to the effect that there is no data to be provided, the appellant could have given opportunity to make his submission by clearly stating that there is no question of providing any data and on the other hand, he could have given the opportunity to substantiate his claim on the basis of the documents produced by the applicant". 2

Further, in substantiating the lack of inventive step ground, the board criticized the Controller for stating bald and vague reasons without getting into the details of the entire document.

The Efficacy conundrum

A careful reading of the description of the corresponding PCT application (as the Indian application is not accessible in IPAIRS website) reveals that the bisulfate salt of vorapaxar is more stable, exhibit improved thermodynamic properties and consistent physical properties than its parent compound. It is worthy to note that the patentability of a crystalline polymorph form of a compound was a matter of dispute in relation with the Section 3(d) of the Indian Patent Act, in the matter of Novartis' Glivec patent application.

Keeping in mind, the lack of therapeutic efficacy as one of the reason for refusal of Schering's patent it is pertinent to discuss in brief on Section 3(d) and interpretation of the term therapeutic efficacy. It is a well known fact that the concept of 'efficacy' is very vague under any patent regime in the world. Such an in-determinate status of 'efficacy' leaves discretion in application in the hands of the patent authorities which results in misconception, legal uncertainty, corruption thus leading to welfare loss. The Supreme Court's decision on Novartis's Glivac case made it crystal clear that efficacy in the context of Section 3(d) should be construed as therapeutic efficacy. The interpretation of the word 'efficacy' is a pivotal factor with regards to Section 3(d). The main section requires 'enhancement of known efficacy' and the explanation section requires the derivatives 'to differ significantly in properties with regards to efficacy'. The standard of proof regarding efficacy is an insurmountable requirement as there is an uncertainty regarding what quantum of 'enhanced efficacy' would be 'significant' as well as the properties regarding efficacy.

Though the section 3(d) requirements are territorial, the introduction of product patents in India since 2005 requires the foreign applicants via PCT to provide proof for efficacy along with their application. The current standard of proof required by the system is very unclear. Submission of pre-clinical trials or lab tests are easier as standards of proof rather than conducting full fledged clinical trials and generate results by that way (normal method to obtain drug regulatory approval)3. Comparing the efficacy of the substance with an earlier known substance is undependable and unethical.

Information pertaining to the therapeutic efficacy are gathered from clinical trials much later in the developmental process of a drug. Hence to provide information on clinical trails at the stage of filing of patent application is a tedious procedure. Also, carrying out full fledged clinical trials to establish efficacy during the discovery process before the filing of patent application would jeopardize the novelty aspect of the invention. The public disclosure of the clinical trails restricts the filing of results within a year of its disclosure. One year time is quite impossible to complete many clinical trials and hence makes the process burdensome.


With regards to Section 15, IPAB has implemented 'Principle of Natural Justice' by setting aside the order of the Assistant Controller and directed the Patent office to consider the matter afresh by affording sufficient opportunity to the applicant to substantiate or amend their claims. The second ground of contention in Schering's case is the crucial therapeutic efficacy which is a serious matter of concern. Efficacy directly determines patentability and other related regimes such as Drugs (Control) Act, etc. Though it is a cumbersome requirement of Section 3(d) of Indian Patents Act, proof of efficacy for the crystalline form of drugs is required for the applicants to surmount section 3(d) without the trepidation of their patents getting rejected/refused/invalidated in the hands of patent authorities.


1. Section 15 of the Indian Patents Act 1970



The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions